A part of Watch Media

MedWatchFriday27 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
12/08/2022at 12:55

Genmab postpones crucial cancer candidate decision following Abbvie exit

For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.
Photo: PR / Genmab
by mikkel holmgaard winding, translated by daniel pedersen

The collaboration between Genmab, a Danish biotech company, and US-based Abbvie entails the development of a string of molecules – which was recently cut a little shorter when Abbvie decided to discontinue the shared efforts on one candidate in particular.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: PR / Genmab

    Abbvie withdraws from cancer candidate collaboration with Genmab

    For subscribers

  • Genmab og partneren Janssen planlægger et sammenlignende studie mellem Hexabody-CD38 og Darzalex Faspro. | Photo: PR / Genmab

    Genmab to measure growth hope against bestseller

    For subscribers

  • Photo: Joost Melis / Genmab / PR

    Genmab beats expectations across the board

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
  • AGC's Japanese and Danish factories to produce German biotech firm's drug candidate
  • AGC Biologics breaks ground on USD 190m Danish factory

For subscribers

Per Wold-Olsen, outgoing chairman of GN's board | Foto: Mik Eskestad
Hearing health

GN's veteran chairman to retire

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Photo: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

For subscribers

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Photo: Phillips-medisize
Medtech

US medtech group expands production in Denmark

For subscribers

Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Photo: Mc2 Therapeutics / Pr
Pharma & biotech

MC2 Therapeutics CEO steps down as board member

For subscribers

Photo: Sebastian Kahnert/AP/Ritzau Scanpix
Pharma & biotech

Atrogi doses first patient in diabetes study

For subscribers

Further reading

"We’re building a team, we already have a well founded set-up, and we’re already testing every procedure and system, because this will be the most important milestone of the year,” says van de Winkel. | Foto: PR / Genmab
Pharma & biotech

CEO Jan van de Winkel: New cancer drug is Genmab's most important milestone next year

Genmab expects to launch epcoritamab in the US and the EU in 2023.

For subscribers

Foto: PR / Genmab
Pharma & biotech

Eyes have been opened to the Genmab-Biontech collaboration, says CEO

The companies’ partnership is moving into a ”more promising phase,” and investors have begun to pay attention, says Genmab CEO Jan van de Winkel while championing the collaborative approach.

For subscribers

Foto: Joost Melis / Genmab / Pr
Pharma & biotech

Three Genmab cancer drugs close in on big milestones in 2023

An approval of drug candidate epcoritomab is Genmab’s biggest New Year’s resolution – but three other cancer candidates also have development goals in 2023.

For subscribers

Latest news

  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
  • US medtech group expands production in Denmark – 26 Jan
  • GN's veteran chairman to retire – 26 Jan
  • MC2 Therapeutics CEO steps down as board member – 26 Jan
  • Atrogi doses first patient in diabetes study – 26 Jan
  • FDA approves ALK's house dust mite tablet for teens – 25 Jan
  • Bavarian Nordic featured on Cowen list of 2023 biotech favorites – 25 Jan
  • Biontech inks deal with UK on sped-up cancer trials – 25 Jan
  • FDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccine – 25 Jan
See all

Jobs

  • Head of Regulatory Affairs Danmark

  • Commercial Director

  • Senior Regulatory Affairs Professional

  • Principal Laboratory Technologist

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Lead Data Architect

  • Head of International Sales

See all jobs

Jobs

  • Head of Regulatory Affairs Danmark

  • Commercial Director

  • Senior Regulatory Affairs Professional

  • Principal Laboratory Technologist

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Lead Data Architect

  • Head of International Sales

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge